Cargando…

Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma

Malignant mesothelioma is an aggressive asbestos-induced cancer, and affected patients have a median survival of approximately one year after diagnosis. It is often difficult to reach a conclusive diagnosis, and ancillary measurements of soluble biomarkers could increase diagnostic accuracy. Unfortu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mundt, Filip, Johansson, Henrik J., Forshed, Jenny, Arslan, Sertaç, Metintas, Muzaffer, Dobra, Katalin, Lehtiö, Janne, Hjerpe, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945903/ https://www.ncbi.nlm.nih.gov/pubmed/24361865 http://dx.doi.org/10.1074/mcp.M113.030775

Ejemplares similares

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
por: Mundt, Filip, et al.
Publicado: (2014)

Multiplex Soluble Biomarker Analysis from Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2020)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
por: Szulkin, Adam, et al.
Publicado: (2014)

Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
por: Javadi, Joman, et al.
Publicado: (2021)

MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
por: Ak, Guntulu, et al.
Publicado: (2015)

Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2021)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells
por: Szatmári, Tünde, et al.
Publicado: (2012)

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
por: Mansour, Mohammed S. I., et al.
Publicado: (2021)

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma
por: Metintaş, Muzaffer, et al.
Publicado: (2022)

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
por: Moretti, Gabriele, et al.
Publicado: (2021)

Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
por: Hillerdal, Carl-Olof, et al.
Publicado: (2017)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma
por: Ötvös, Rita, et al.
Publicado: (2015)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
por: Palstrøm, Nicolai B., et al.
Publicado: (2023)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Management of Pleural Effusion Secondary to Malignant Mesothelioma
por: Musso, Valeria, et al.
Publicado: (2021)

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
por: Darai-Ramqvist, Eva, et al.
Publicado: (2013)

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
por: Otoshi, Takehiro, et al.
Publicado: (2017)

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
por: Hjerpe, Anders, et al.
Publicado: (2022)

Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma
por: Zallocco, Lorenzo, et al.
Publicado: (2022)

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
por: Akgun, Hakan, et al.
Publicado: (2021)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2020)

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
por: Beije, Nick, et al.
Publicado: (2017)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

A case of pleural mesothelioma with effusive-constrictive pericarditis.
por: Weir, N. A., et al.
Publicado: (2001)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1
por: Szatmári, Tünde, et al.
Publicado: (2017)

Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion
por: Chen, Kuan-Yuan, et al.
Publicado: (2016)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review
por: Zhang, Man, et al.
Publicado: (2021)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f9gqc40orumacka1astrk4i09d